Skip to Main Content


Cabotegravir is an integrase inhibitor that has been approved for use in the United States, Canada, and in the European Union.

It is intended to be given with rilpivirine. The advantage of this combination is that it is complete therapy for patients in whom the viral load is stable and suppressed (< 50 copies) on their current regimen, which is then stopped in favor of cabotegravir/rilpivirine.

Fostemsavir, an attachment inhibitor, and ibalizumab, a monoclonal antibody, are FDA approved specifically for heavily treated adults with multidrug-resistant HIV who are not responding to their existing regimen.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.